Development of Innovative COVID-19 Therapies Needs Additional Public Funding to Help Patients in the Short-Term (in German Only)
January 8, 2021Entwicklung innovativer COVID-19-Medikamente bedarf weitergehender öffentlicher Förderung, um Patienten schnell zu helfen Deutschland, 08. Januar 2021 – Die Initiative BEAT-COV…Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838
December 12, 2017Planegg-Martinsried, Germany, December 12th, 2017 – Immunic AG (Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, today announced…Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million
September 5, 2017Planegg-Martinsried, Germany, September5th, 2017 – Immunic AG (Immunic Therapeutics), a clinical stage private biotech company in Martinsried near Munich, Germany, today announced…Immunic Adds EUR 4 Million in Funding to Further Boost Development
February 1, 2017Planegg-Martinsried and Magdeburg, Germany, February 1st, 2017 – Immunic AG (Immunic Therapeutics), a recently founded private biotech company in Martinsried near Munich,…Immunic strengthens Management Team and Supervisory Board
January 9, 2017Two executives with deep understanding of the immunology field, and with experience in the IMU-838/IMU-366 development programs add to the…